< 生产厂家价格 >

依碳氯替泼诺

依碳氯替泼诺用途

Loteprednol Etabonate具有抗炎活性,可用于眼科学。

点击显示

依碳氯替泼诺名称

[ CAS 号 ]:
82034-46-6

[ 中文名 ]:
依碳氯替泼诺

[ 英文名 ]:
Loteprednol etabonate

[中文别名 ]:

[英文别名 ]:

Loteprednol (INN)
Loteprednolum
Loteprednol Etabonate
Loteprednol [INN:BAN]
HGP 1
loteprednol

依碳氯替泼诺生物活性

[ 描述 ]:

Loteprednol Etabonate具有抗炎活性,可用于眼科学。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 糖皮质激素受体

研究领域 >> 炎症/免疫

天然产物 >> 其他

[参考文献]

[1]. Noble S, Goa KL. Loteprednol etabonate: clinical potential in the management of ocular inflammation. BioDrugs. 1998 Oct;10(4):329-39.

[2]. Szelenyi I, Hochhaus G, Heer S et al. Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20.

[3]. Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie. 2000 Mar;55(3):178-83.

[4]. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008 Apr;92(4):455-9.

[5]. Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012;2012:789623.

[6]. Loteprednol

[相关活性小分子]

依碳氯替泼诺物理化学性质

[ 密度 ]:
1.3±0.1 g/cm3

[ 沸点 ]:
600.1±55.0 °C at 760 mmHg

[ 熔点 ]:
220.5-223.5ºC

[ 分子式 ]:
C₂₄H₃₁ClO₇

[ 分子量 ]:
466.952

[ 闪点 ]:
316.7±31.5 °C

[ 精确质量 ]:
466.175842

[ PSA ]:
99.13000

[ LogP ]:
3.17

[ 外观性状 ]:
white to beige

[ 蒸汽压 ]:
0.0±3.9 mmHg at 25°C

[ 折射率 ]:
1.571

[ 储存条件 ]:
-20°C Freezer

[ 水溶解性 ]:
DMSO: soluble5mg/mL, clear (warmed)

依碳氯替泼诺MSDS

详细MSDS(安全技术说明书)

依碳氯替泼诺安全信息

[ 危害码 (欧洲) ]:
Xi

[ 危险品运输编码 ]:
NONH for all modes of transport

[ 海关编码 ]:
2937229000

依碳氯替泼诺海关

[ 海关编码 ]: 2937229000

依碳氯替泼诺文献

Topical cyclosporine a 1% for the treatment of chronic ocular surface inflammation.

Eye Contact Lens 40(5) , 283-8, (2014)

To evaluate the use of topical cyclosporine A (CsA) 1% emulsion in the treatment of chronic ocular surface inflammation (OSI).We conducted a retrospective chart review of patients with various forms o...

Small-incision lenticule extraction for myopia: results of a 12-month prospective study.

Optom. Vis. Sci. 92(1) , 123-31, (2015)

To analyze the safety, efficacy, stability, and predictability of small-incision lenticule extraction to correct myopia.Patients were evaluated preoperatively and then at 1 day, at 2 weeks, and at 1, ...

Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.

J. Cataract Refract. Surg. 39(2) , 168-73, (2013)

To evaluate the efficacy of loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the control of postoperative inflammation in patients having routine cataract surgery.Private practice, Stil...

更多文献